William Oh

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.

Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.

The evolving role of estrogen therapy in prostate cancer.

To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants.

Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants.

Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer.

A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.

An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer.

Prevention of intraventricular hemorrhage by indomethacin in male preterm infants.

Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.

Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003.

Inhaled nitric oxide for premature infants with severe respiratory failure.

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.

Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center.

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.

Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy.

Transitional cell carcinoma of the upper uroepithelial tract.

High-risk localized prostate cancer: integrating chemotherapy.

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.

Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.

Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.

Chemotherapy for high-risk localized prostate cancer.

Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial.

Recent progress in hormonal therapy for advanced prostate cancer.

Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.

Oral probiotics prevent necrotizing enterocolitis.

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.

Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.

Carboplatin for stage I seminoma.

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.

Development of an integrated prostate cancer research information system.

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.

The medical management of prostate cancer: a multidisciplinary team approach.

Effects of sample dilution, peroxidase concentration, and chloride ion on the measurement of unbound bilirubin in premature newborns.

Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.

Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer.

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice.

Trends in neonatal morbidity and mortality for very low birthweight infants.

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

Timing of umbilical cord clamping at birth in full-term infants.

Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.

Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.

Human milk intake and retinopathy of prematurity in extremely low birth weight infants.

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.

Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.

Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.

Ontogeny of bilirubin-binding capacity and the effect of clinical status in premature infants born at less than 1300 grams.

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.

Use of androgen deprivation therapy for metastatic prostate cancer in older men.

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy.

Relationship between serum adiponectin and prostate cancer grade.

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.

CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.

Maternal depression is a common complication among pregnant women occurring approximately 2-3% of this population. Introduction.

What is the current status of second-line chemotherapy for castration-resistant prostate cancer?

Aggressive vs. conservative phototherapy for infants with extremely low birth weight.

Absence of relationship between steroid hormone levels and prostate cancer tumor grade.

Twin gestation and neurodevelopmental outcome in extremely low birth weight infants.

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.

Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

Functional enhancers at the gene-poor 8q24 cancer-linked locus.

The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.

Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?

Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface.

Neoadjuvant and adjuvant therapies in prostate cancer.

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.

The 20th Biennial International Perinatal Collegium. Introduction.

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.

Cabazitaxel.

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.

Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.

Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.

Genome-wide association study of prostate cancer mortality.

Sixty years of CA: a cancer journal for clinicians.

Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy.

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.

Cancer therapy from bench to bedside.

Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.

Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.

Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes.

Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants?

Neurodevelopmental outcomes of triplets or higher-order extremely low birth weight infants.

Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Early nutrition mediates the influence of severity of illness on extremely LBW infants.

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.

PC3 is a cell line characteristic of prostatic small cell carcinoma.

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study.

Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.

Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

Castration-resistant prostate cancer: new science and therapeutic prospects.

Cytokines and neurodevelopmental outcomes in extremely low birth weight infants.

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.

Secondary hormonal therapy in men with castration-resistant prostate cancer.

Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants.

Hemodynamic effects of delayed cord clamping in premature infants.

Overcoming castration resistance in prostate cancer.

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.

The emerging role of circulating tumor cell detection in genitourinary cancer.

Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.

Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.

Trends in the use of cytoreductive nephrectomy in the United States.

Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.

Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.

Bevacizumab treatment of prostate cancer.

Atypical metastases from prostate cancer: 10-year experience at a single institution.

Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks.

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Emerging personalized approaches for the management of advanced urothelial carcinoma.

Fluid and electrolyte management of very low birth weight infants.

Early onset neonatal group B streptococcal sepsis.

Vitamin A Supplementation in Extremely Low-Birth-Weight Infants: Subgroup Analysis in Small-for-Gestational-Age Infants.

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration.

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

New paradigms in microtubule-mediated endocrine signaling in prostate cancer.

Cord milking at delivery improves the iron status of term infants at 6 weeks.

Castration-resistant prostate cancer: AUA Guideline.

The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

Metabolic complications with the use of mTOR inhibitors for cancer therapy.

Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.

Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.

Behavioral and socioemotional competence problems of extremely low birth weight children.

Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants.

Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

Not all "term" infants are created equal.

TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.

Perfusion imaging of spinal cord contusion: injury-induced blockade and partial reversal by β2-agonist treatment in rats.

Adverse event reporting in cancer clinical trial publications.

Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.

Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.

Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II-III Resectable Disease.

Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.

T2 muscle-invasive bladder cancer.

Effects of placental transfusion in extremely low birthweight infants: meta-analysis of long- and short-term outcomes.

The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer.

Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.

Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.

Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).

Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.

Adult cancer clinical trials that fail to complete: an epidemic?

Use of crowdsourcing for cancer clinical trial development.

Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.

Geographic accessibility to clinical trials for advanced cancer in the United States.

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.

Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care.

Clinical trial awareness: Changes over time and sociodemographic disparities.

Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.

Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?

Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer.

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.